RT Journal Article
SR Electronic
T1 Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4907
OP 4912
DO 10.21873/anticanres.15996
VO 42
IS 10
A1 TAKURO OKADA
A1 TAKASHI MATSUKI
A1 CHIHIRO FUSHIMI
A1 ISAKU OKAMOTO
A1 HIROKI SATO
A1 TAKAHITO KONDO
A1 KUNIHIKO TOKASHIKI
A1 TATSUYA ITO
A1 TATSUO MASUBUCHI
A1 YUICHIRO TADA
A1 KOUKI MIURA
A1 KENJI HANYU
A1 GO OMURA
A1 HIDEKI TAKAHASHI
A1 TAKU YAMASHITA
A1 NOBUHIKO ORIDATE
A1 KIYOAKI TSUKAHARA
YR 2022
UL http://ar.iiarjournals.org/content/42/10/4907.abstract
AB Background/Aim: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive R/M HNSCC has not been shown. Therefore, this study compared the efficacy and safety of nivolumab for platinum-refractory and platinum-sensitive R/M HNSCC. Patients and Methods: This was a retrospective study of patients who received nivolumab for R/M HNSCC who had been previously treated with platinum-based anticancer drugs. Patients were divided into a platinum-sensitive and a platinum-refractory group, and progression-free survival (PFS), overall survival (OS), the overall response rate (ORR) [complete response (CR) + partial response (PR)], the disease control rate (DCR) (CR + PR + stable disease), and the incidence of immune-related adverse events (irAEs) were compared between the two groups. Results: We included 88 patients with squamous cell carcinoma: 60 with platinum-refractory disease and 28 with platinum-sensitive disease. The median PFS in the platinum-refractory and platinum-sensitive groups were 2.7 months and 5.3 months, respectively (p=0.03), and the median OS were 8.8 months and 17.1 months, respectively (p=0.06). There were no significant differences in the ORR, DCR, or incidence of irAEs between the two groups (p>0.99, p=0.11, and p>0.99, respectively). Conclusion: Nivolumab is a safe and effective treatment for platinum-sensitive R/M HNSCC.